Biomedical subjects

Y L Lim

Publications and source records attributed to Y L Lim.

At least 19 recordsLinked to original sources

PubMed2006

Non-invasive multislice computed tomography coronary angiography for imaging coronary arteries, stents and bypass grafts.

Abstract Multislice computed tomography (MSCT) is evolving rapidly and available data suggest that MSCT coronary angiography may be a reliable and accurate non-invasive imaging modality of coronary arteries. Current generations of MSCT scanners have high sensitivity and specificity for diagnosing native coronary artery disease and coronary bypass graft occlusion. The performance of MSCT in the evaluation of stent patency is still being assessed. In comparison with conventional selective coronary angiography (SCA), MSCT is non-invasive, cheaper and it has the advantages of imaging plaque compositions as well as assessment of luminal patency. Nevertheless, the role of MSCT in the management of coronary artery disease is yet to be fully defined.

Coronary Angiography↗

PubMed2005

Serious cutaneous adverse reactions to traditional Chinese medicines.

INTRODUCTION: Serious cutaneous adverse reactions to traditional medicines are not well described or reported in the literature, despite growing use of these medicines. METHODS: This is a case series of four patients who were found to have various serious cutaneous adverse reactions to the traditional Chinese medicines that they had taken. RESULTS: In this series, there was a patient with toxic epidermal necrolysis from traditional Chinese medicine, another with acute generalised exanthematous pustulosis from piroxicam and salicylate-contaminated traditional Chinese medicine, and two patients with drug hypersensitivity syndrome--one from traditional Chinese medicine and the other from phenylbutazone-adulterated traditional Chinese medicine. CONCLUSION: The series illustrates that serious cutaneous adverse reactions do occur with traditional medicines and emphasises the importance of being aware of such reactions.

Adult↗

PubMed2003

Factors contributing to variation in lipoprotein (a) in Melbourne Anglo-Celtic population.

AIM: The purpose of this report is to survey the factors contributing to variation in lipoprotein(a) (Lp(a)) in a population-based sample of Anglo-Celtic Melburnians. RESULTS: The plasma Lp(a) levels were highly skewed towards low levels in this population, with a median of 156 mg/l and a mean of 262 mg/l. Approximately 33% had plasma Lp(a) above the threshold value of 300 mg/l, while 35% had Lp(a) levels below 100 mg/l. The most commonly occurring phenotype was apo(a) S3. In this phenotype, Lp(a) concentrations ranged from 10 to 596 mg/l. Lp(a) was consistently associated with diastolic blood pressure, systolic blood pressure, total protein, albumin and nitrogen excretion in the 40-60 y age group. Multiple stepwise regression analyses, in non-dietary factors, were used to explain about 13% of the variance in Lp(a) (19% in men and 23% in women). Remarkably, in the <40 y age group, non-dietary factors may account for 86% of the variance in Lp(a) and dietary factors, analysed separately, 46%. Thus, although Lp(a) is mainly genetically determined, there are clearly other factors which contribute to variations in Lp(a) concentrations.

Adult↗

PubMed2003

Restenosis in percutaneous coronary intervention--is drug-eluting stent the answer?

The long-term success of percutaneous coronary intervention in the treatment of coronary artery disease is hampered by the occurrence of restenosis, which often necessitates repeat hospitalisations or coronary interventions. The advent of drug-eluting stents, particularly those coated with sirolimus and paclitaxel, may be the breakthrough in the battle against restenosis that interventional cardiologists have been waiting for, and we review the currently available evidence for this. Despite the growing enthusiasm, we should not forget that this new technology is still in its relative infancy, and there remain many unanswered questions, particularly about the long-term effect of using these stents.

Angioplasty, Balloon, Coronary↗

PubMed2002

Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis.

OBJECTIVE: To compare the early and late outcomes of primary percutaneous transluminal coronary angioplasty (PTCA) with fibrinolytic treatment among diabetic patients with acute myocardial infarction (AMI). DESIGN: Retrospective observational study with data obtained from prospective registries. SETTING: Tertiary cardiovascular institution with 24 hour acute interventional facilities. PATIENTS: 202 consecutive diabetic patients with AMI receiving reperfusion treatment within six hours of symptom onset. INTERVENTIONS: Fibrinolytic treatment was administered to 99 patients, and 103 patients underwent primary PTCA. Most patients undergoing PTCA received adjunctive stenting (94.2%) and glycoprotein IIb/IIIa inhibition (63.1%). MAIN OUTCOME MEASURES: Death, non-fatal reinfarction, and target vessel revascularisation at 30 days and one year were assessed. RESULTS: Baseline characteristics were similar in these two treatment groups except that the proportion of patients with Killip class III or IV was considerably higher in those treated with PTCA (15.5% v 6.1%, p = 0.03) and time to treatment was significantly longer (103.7 v 68.0 minutes, p < 0.001). Among those treated with PTCA, the rates for in-hospital recurrent ischaemia (5.8% v 17.2%, p = 0.011) and target vessel revascularisation at one year (19.4% v 36.4%, p = 0.007) were lower. Death or reinfarction at one year was also reduced among those treated with PTCA (17.5% v 31.3%, p = 0.02), with an adjusted relative risk of 0.29 (95% confidence interval 0.15 to 0.57) compared with fibrinolysis. CONCLUSION: Among diabetic patients with AMI, primary PTCA was associated with reduced early and late adverse events compared with fibrinolytic treatment.

Abciximab↗

PubMed2002

Gender differences in outcome after an acute myocardial infarction in Singapore.

OBJECTIVES: To characterise gender and age-related differences in presentation and outcome after an acute myocardial infarction (AMI). DESIGN: Data were derived retrospectively from the Singapore Myocardial Infarction Registry from 1988 through 1997. This database comprised all AMI cases for ages between 20 and 64 years (group A). For approximately three months a year, data were also collected for all AMI cases above the age of 64 years (group B). There were 13,048 and 4,425 cases in groups A and B respectively. RESULTS: In age - standardised AMI rates, males outnumbered females by a factor of 4.0 and 1.7 for groups A and B respectively.The median age of presentation was higher in females for both age groups being 58 years versus 54 years for group A and 75 years versus 72 years for group B. Younger females had worse survival at 28 days and were more likely to have prior ischaemic heart disease and require resuscitation. They were also more likely to have atypical symptoms. Previous myocardial infarction was not different between the sexes in both groups. Among the older age group, there was no gender difference in prior ischaemic heart disease, 28-day survival and requirement for resuscitation. CONCLUSION: Women who have AMI tend to be older than men. Gender differences are age-specific. Women who are 64 years and below have more atypical symptoms, prior ischaemic heart disease and worse prognosis than men after AMI. These differences are not seen in those over the age of 64.

Adult↗

PubMed2001

Alpha1A- and alpha1B-adrenoceptors are the major subtypes in human saphenous vein.

In this study we analyzed the different alpha1-adrenoceptor (AR) subtypes present in human saphenous vein (HSV) using reverse transcription polymerase chain reaction (RT-PCR), DNA-DNA hybridization analysis and functional affinities for alpha-AR antagonists. DNA-DNA hybridization analysis of RT-PCR amplification products confirmed the presence of alpha1A- and alpha1B-ARs, and low levels of alpha1D-AR in HSV. The functional results showed: (1) prazosin, the selective alpha1-AR antagonist, phentolamine, the alpha1- and alpha2-ARs antagonist, WB 4101 and 5-MU, the selective alpha1A-AR subtype antagonists were potent, competitive antagonists of noradrenaline (NA)-induced contraction (pA2 values of 11.03, 8.06, 9.02 and 8.34, respectively). (2) Alpha1-AR-induced contraction was sensitive to the alkylating effects of CEC (the alpha1B and alpha1D-AR subtypes antagonist) and (3) The selective alpha1D-AR subtype antagonist BMY displayed low affinity (pA2 values of 6.44). This indicates that the contractile response of the HSV to alpha1-AR-induced is predominantly mediated by both alpha1A and alpha1B-AR subtypes. This was also supported by the good relationship between pA2 values from the present study and reported binding affinities (pKi) values of various alpha1-AR subtype antagonists with cloned human alpha1A- and alpha1B-AR subtypes (r=0.89 and r=0.98, respectively), but not the alpha1D-AR subtype (r=0.67). Our results indicate that alpha1A- and alpha1B-ARs are the main functional and expressed receptor subtypes in HSV.

Adrenergic alpha-Antagonists↗

PubMed2001

Effects of micromolar concentrations of manganese, copper, and zinc on alpha1-adrenoceptor-mediating contraction in rat aorta.

To determine the influences of the Mn, Cu, and Zn on alpha1-adrenoceptor (AR)-mediated vasoconstriction, we investigated their effects on vasoconstriction produced by the alpha1-AR agonist phenylephrine in isolated rings of rat thoracic aorta. The cumulative concentration-contraction curves for phenylephrine were obtained in the absence and presence of Mn (0.3, 1, 3 microM), Cu (1, 10, 16 microM), and Zn (0.3, 1, 10 microM). Mn, Cu, and Zn each inhibited phenylephrine-mediated contraction in a dose-dependent manner. The maximal phenylephrine-induced contraction was significantly reduced by the pretreatment of the arterial rings with 10 and 16 microM Cu (p<0.05). The results suggest that variations in the plasma concentrations of metal might lead to changes in alpha1-AR-mediated constrictive response.

Adrenergic alpha-1 Receptor Agonists↗

PubMed2000

Inhibition of restenosis with beta-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT).

BACKGROUND: Intracoronary gamma- and beta-radiation have reduced restenosis in animal models. In the clinical setting, the effectiveness of beta-emitters has not been studied in a broad spectrum of patients, particularly those receiving stents. METHODS AND RESULTS: A prospective, randomized, sham-controlled study of intracoronary radiotherapy with the beta-emitting (32)P source wire, using a centering catheter and automated source delivery unit, was conducted. A total of 105 patients with de novo (70%) or restenotic (30%) lesions who were treated by stenting (61%) or balloon angioplasty (39%) received 0 (control), 16, 20, or 24 Gy to a depth of 1 mm in the artery wall. Angiography at 6 months showed a target site late loss index of 11+/-36% in radiotherapy patients versus 55+/-30% in controls (P:<0.0001). A low late loss index was seen in stented and balloon-treated patients and was similar across the 16, 20, and 24 Gy radiotherapy groups. Restenosis (>/=50%) rates were significantly lower in radiotherapy patients at the target site (8% versus 39%; P:=0.012) and at target site plus adjacent segments (22% versus 50%; P:=0.018). Target lesion revascularization was needed in 5 radiotherapy patients (6%) and 6 controls (24%; P:<0.05). Stenosis adjacent to the target site and late thrombotic events reduced the overall clinical benefit of radiotherapy. CONCLUSIONS: beta-radiotherapy with a centered (32)P source is safe and highly effective in inhibiting restenosis at the target site after stent or balloon angioplasty. However, minimizing edge narrowing and late thrombotic events must be accomplished to maximize the clinical benefit of this modality.

Angioplasty, Balloon, Coronary↗

PubMed2000

Stent placement for non-STRESS/BENESTENT lesions: a critical review.

Stenting lesions with favorable characteristics as required for inclusion in the STRESS/BENESTENT trials have yielded superior results to that of PTCA alone. Results for less favorable lesions such as in small vessels, diffuse disease, ostial disease, and saphenous vein grafts are less well established. This review seeks to analyze available data for stent placement in this subset of non-STRESS/BENESTENT lesions.

Angioplasty, Balloon, Coronary↗

PubMed2000

Cost-effectiveness and accuracy of exercise stress echocardiography in the non-invasive diagnosis of coronary heart disease.

BACKGROUND: Exercise stress echocardiography (ESE) is a more recent form of totally non-invasive stress testing which like exercise thallium SPECT scintigraphy (ETS) was developed to overcome the known limitations of ECG stress testing, namely the limited diagnostic accuracy and the inability of ECG stress testing to site the region of coronary artery disease (CAD) induced ischaemia. AIMS: To determine the sensitivity and specificity (and overall accuracy) of ESE in a group of patients referred for ETS imaging and compare the relative costs of each technique. METHODS: One hundred and fifteen patients referred for ETS consented to a simultaneous ESE. Of this group, 59 patients underwent coronary angiography which was utilised as the gold standard. RESULTS: The feasibility of ESE was 97% (112 of 115 patients of the total study population and 57 of the 59 patients who underwent coronary angiography). Of the 59 patients undergoing coronary angiography, the sensitivity of ESE and ETS were not significantly different (84.1% versus 91.3% respectively). However, despite the apparent marked difference in specificity (92.3% versus 61.5% respectively), p = NS (Fisher's exact test) as there were only 13 normals in the group who underwent coronary angiography. Overall accuracy was also closely similar (86.0% versus 84.7% respectively) and therefore also not significantly different. By contrast, agreement with coronary angiography as measured by the kappa statistic (kappa +/- SEk) was good for ESE (0.66 +/- 0.11) but only moderate for ETS (0.54 +/- 0.13). Moreover, there was a cost saving of at least $594.00 per patient in favour of ESE. CONCLUSION: ESE is a totally non-invasive, sensitive, specific and cost-effective imaging modality for the detection and localisation of CAD.

Aged↗

PubMed2000

Cardiac marker point-of-care testing: evaluation of rapid on-site biochemical marker analysis for diagnosis of acute myocardial infarction.

INTRODUCTION: Up to 40% of patients with acute myocardial infarction (AMI) present with non-diagnostic electrocardiograms (ECGs). The diagnosis in such cases is usually made with the aid of biochemical markers. Newer and more rapid assays for such markers have now enabled testing to be done on-site instead of in the laboratory. This potentially enables the clinician to rapidly diagnose and triage patients. We evaluated the diagnostic precision of this point-of-care testing strategy using one such analyser, the Stratus CS (Dade Behring) in a prospective study. MATERIALS AND METHODS: The study population consisted of 51 consecutive patients admitted for suspected AMI with non-diagnostic ECGs. Two blood samples from each patient were drawn simultaneously on admission. The first sample was assayed for myoglobin, troponin I (TnI) and creatine kinase-MB (CKMB) mass by the point-of-care instrument (Stratus CS), and the second sample was sent for standard testing for AMI, comprising a troponin-T (TnT) qualitative test and the analysis of CKMB by the hospital laboratory. Utilising the recommended cut-off values for the individual assays, the results of these 2 sets of tests were evaluated based on whether they were positive or negative for AMI and compared against the patient's final diagnosis at discharge. Various combinations of markers were assessed. RESULTS: On evaluation of individual markers, myoglobin was the most sensitive (75%) at 0 to 6 hours after onset of symptoms, while TnI (95%), TnT (80%) and CKMB-mass (90%) performed better at 7 to 12 hours. Point-of-care testing utilising a combination of markers was highly sensitive and specific. Both dual-marker panels of myoglobin with TnI and myoglobin with CKMB-mass yielded equivalent overall sensitivities and specificities of 90% and 95% respectively. A triple-marker panel of myoglobin, TnI and CKMB-mass had a sensitivity of 93% and specificity of 95%. All point-of-care testing panels had good positive and negative predictive values, and showed comparable diagnostic efficacy with the standard testing presently utilised for the diagnosis of AMI. The average time for results to become available was up to 26 minutes for point-of-care testing and 65 minutes for standard testing. CONCLUSION: Point-of-care testing utilising a panel of 2 or 3 cardiac markers has comparable diagnostic precision to the presently utilised testing strategy for AMI, with earlier availability of results.

Adult↗

PubMed1999

Angiographic restenosis rate in patients with chronic total occlusions and subtotal stenoses after initially successful intracoronary stent placement.

The 5-month angiographic in-stent restenosis rate did not differ between patients with chronic total occlusions (n = 43) and subtotal stenoses (n = 43) equally matched for diabetes status, exact stent design, final expanded stent diameter, stent length, and residual percent diameter stenosis after stent placement; it was 32.5% and 27.9% for those with chronic total occlusions and subtotal stenoses, respectively (p = 0.638). Furthermore, the stent occlusion rate (4.6% vs 6.9%, respectively) was low in both patient groups.

Angioplasty, Balloon, Coronary↗

PubMed1999

Immediate and mid-term results after MultiLink stent implantation in native coronary arteries.

Different stent designs have widely disparate characteristics that may exert a positive or negative impact on their early and mid-term outcomes. The MultiLink stent (Guidant/Advanced Cardiovascular Systems, Santa Clara, CA) is a new coronary stent with only very limited data. In this report, we examined the results of 50 consecutive patients treated with 57 premounted sheathless MultiLink stents in 53 native coronary arteries with reference diameter > or =2.7 mm. Successful stenting was achieved in 98% of patients, resulting in an improvement in diameter stenosis from 91%+/-11% to 1%+/-3% (P = 0.0001). At 1 month, there was no death, myocardial infarction, or stent thrombosis. Angiographic restudy at a mean of 5.0+/-1.8 months in 94% of patients revealed an in-stent restenosis rate of 20.7%. The restenosis rates for diabetic patients (vs. nondiabetic patients), type C lesions (vs. type A/B1 lesions), and the use of 35-mm-long stents (vs. 15-mm-long stents) were 45.4% (14.3%), 56% (< or =11%), and 80% (8.8%), respectively (P < 0.05). In conclusion, the present study demonstrates that the MultiLink stent has an excellent performance profile, is associated with a low risk of stent thrombosis in native coronary vessels, and yields a favorable restenosis rate, particularly after the use of short (15 mm) stents to treat simple lesions.

Aged↗

PubMed1999

Curative therapy of cardiac tachyarrhythmias with catheter ablation--a review of the experience with the first 1000 patients.

INTRODUCTION: Cardiac tachyarrhythmias present as supraventricular or ventricular tachycardia. Catheter ablation has completely revolutionised the treatment of patients with these arrhythmias. METHOD: We reviewed the experience of radiofrequency catheter ablation in a single centre. RESULTS: A total of 1,022 patients underwent radiofrequency catheter ablation from October 1991-December 1997. There were 480 patients who had AV nodal re-entrant tachycardia, 429 patients with accessory pathways, 7 patients with both AV nodal re-entrant tachycardia and accessory pathways, 4 patients with both AV nodal re-entrant tachycardia and atrial tachycardia. Twenty-seven patients had atrial tachycardia ablation, 28 had atrial flutter ablation and 11 patients had AV node ablation for atrial fibrillation. The mean age of the supraventricular tachycardia patients was 41 +/- 15 years (10-80 years). The mean duration of procedure was 108 +/- 60 minutes (15 to 480 minutes) and the mean fluoroscopy time was 19 +/- 17 minutes (3-122 minutes). Another 14 patients had ablation for right ventricular outflow tract ventricular tachycardia and 22 patients had ablation for idiopathic left ventricular tachycardia. The mean age of the ventricular tachycardia patients was 35 +/- 14 years (19-65 years). The mean duration of the ventricular tachycardia ablation procedure was 185 +/- 63 minutes (110-285 minutes) and the duration of fluoroscopy was 33 +/- 16 minutes (range 14-68 minutes). Of the 1,022 patients, 1,002 (98%) of the patients were successfully ablated. There were significant complications in less than 1% of the patients and no mortality associated with the procedure. The recurrence rate was 5% and could be successfully reablated when the procedure was repeated. CONCLUSION: Radiofrequency catheter ablation is thus an extremely safe and successful procedure and has replaced drug therapy as the treatment of choice for patients with supraventricular tachycardia and non-ischaemic ventricular tachycardia. It provides curative therapy without the need for life-long drug therapy.

Adolescent↗

PubMed1999

Treatment and prevention of sudden cardiac death--what have we learnt from randomised clinical trials?

Sudden cardiac death is most commonly caused by ventricular tachycardia or fibrillation. Three groups of patients at highest risk for sudden cardiac death are survivors of previous sudden cardiac death, those with recurrent documented episodes of sustained ventricular tachycardia and patients with recurrent syncope of unknown origin. The experience with antiarrhythmic drugs has been discouraging. Only beta-blockers have been shown to unequivocally reduce both arrhythmic and total mortality in randomised trials. Class I antiarrhythmic drugs increase mortality, especially in an ischemic substrate. Class III drugs such as sotalol and amiodarone have had variable success. Racemic sotalol has both beta-blocker as well as Class III actions and some of the benefits may be due to the former effect. D-sotalol which has only pure Class III action, increases mortality in the post myocardial infarction patient. Amiodarone is superior to Class I antiarrhythmic drugs for patients with previous cardiac arrest. In the high-risk myocardial infarction patient, it seems to reduce sudden death but not total mortality. In the cardiac failure patient, the effect of amiodarone on total mortality is controversial. Several randomised trials of implantable cardioverter-defibrillator (ICD) therapy versus drugs have however concluded that the ICD is superior to drugs in reducing total mortality. In comparison with many other high volume therapies used in medicine today, ICD is still a cost-effective therapy.

Adrenergic beta-Antagonists↗

PubMed1998

Midterm angiographic outcome of single-vessel intracoronary stent placement in diabetic versus nondiabetic patients: a matched comparative study.

BACKGROUND: It remains controversial whether diabetes is associated with an increased risk of restenosis after intracoronary stenting. METHODS AND RESULTS: We selected 42 diabetic patients and an equal number of nondiabetic patients with follow-up angiographic restudy after single-vessel stenting, matched for 4 important stent-related and angiographic variables (stent design, reference vessel size and expanded stent diameter, coronary vessel treated, and poststent residual diameter stenosis). The 2 patient groups did not differ in their baseline lesion severity and acute luminal gain. At 5-month angiographic assessment, the observed in-stent restenosis rate was significantly higher in diabetic than nondiabetic patients (40.5% vs 16.7%, P = 0.0157). It was highest in diabetic patients who received small stents <3.0 mm in diameter and intermediate in diabetic patients who received larger stent sizes (55% vs 27%, P = 0.0675). The frequency of restenosis in nondiabetic patients, however, was low; it was 18% and 15% in those who received small stents and larger stents, respectively (P = 0.7823). CONCLUSIONS: Our data suggest that diabetes predisposes to an increased risk of in-stent restenosis, particularly in small vessels.

Coronary Angiography↗

PubMed1998

The Brugada syndrome in a Chinese population.

Sudden cardiac death has been reported in patients with a unique electrocardiographic (ECG) abnormality showing right bundle branch block and ST segment elevation in the precordial leads. This syndrome was first described by Brugada and Brugada and has not been previously described in a Chinese population. We report here the first three cases in Singapore. The first patient was a 49-year-old man who presented with syncope, associated with generalized convulsions. The second patient was a 25-year-old man who complained of palpitations but no syncope. The third patient was a 77-year-old man who presented with recurrent episodes of syncope and collapsed with ventricular fibrillation. All patients had no past cardiac or drug history of note. The neurological examination and investigations were normal. All three patients showed a unique right bundle branch block pattern with ST segment elevation in leads V1-3. The echocardiogram and 24-h ambulatory ECG monitoring, were normal. Single vessel disease was present in the third patient. Electrophysiological studies performed in all three patients were able to induce ventricular fibrillation. The patient with resuscitated cardiac death underwent an implantable cardioverter defibrillator implantation. The importance of this syndrome is that the recognition of the unique ECG pattern enables early identification and treatment of these patients.

Adult↗